<DOC>
	<DOCNO>NCT02469987</DOCNO>
	<brief_summary>Double-blind , single-dose , three-treatment , parallel group design PK comparability study MYL-1402O solution manufacture Mylan compare US EU market Avastin® solution ( bevacizumab ) .</brief_summary>
	<brief_title>Phase I - Pharmacokinetic Comparability Study Healthy Male Volunteers</brief_title>
	<detailed_description>Double-blind , single-dose , three-treatment , parallel group design PK comparability study MYL-1402O solution manufacture Mylan compare US EU market Avastin® solution ( bevacizumab ) total 111 healthy , adult male volunteer ( 37 subject per treatment arm ) . After randomization , subject receive one follow treatment : A single 1 mg/kg dose administer i.v . infusion ( 25 mL approximately 90 minute ) MYL-1402O , equivalent i.v . infusion US market Avastin® ( 1 mg/kg ) , equivalent i.v . infusion EU market Avastin® ( 1 mg/kg ) .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Males age 1855 yr . ( inclusive ) BMI : 19.0 30.0 kg/m2 ( inclusive ) Weight : ≥ 60kg ≤100kg Subjects willing use adequate contraception donate sperm admission clinical research center 6 month post dose . All intermittent medication stop least 14days prior admission clinical research center . All intermittent non topical medication must stop least 30days prior admission clinical research center . Ability willingness abstain ETOH 48hrs prior admission clinical research center . Medical history without significant finding per PI Resting supine systolic BP ≤140mmHg diastolic BP ≤90mmHg ECGs ( via 12 lead ) show NCS finding per PI All clinical laboratory test blood urine , WNL and/or without clinically significant finding Willing/able sign ICF Normal bowel habit Negative medical history regard fecal blood positivity Normal and/or NCS spot protein/creatinine ( PCR ) ratio . Previous participation current study History prior exposure bevacizumab Evidence clinically significant finding Cognitive / mentally impaired handicap would affect ability make inform consent and/or remain compliant requirement trial . History relevant drug and/or food related allergy . History known hypersensitivity bevacizumab recombinant human humanize antibody inactive ingredient . Tobacco product use w/I 1 yr. prior drug administration . History ETOH drug abuse/addiction Positive urine drug ETOH screen opiate , methadone , cocaine , amphetamine include XTC , cannabinoids , barbiturate , benzodiazepine , tricyclic antidepressant ETOH . Average intake 24 unit ETOH / wk . ( 1 unit ETOH equal ~250mL beer , 100mL wine 35mL spirit ) . Consumption food contain poppy seed w/I 48 hr . prior screen admission clinical research center Positive screen Hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibodies antihuman immunodeficiency virus ( HIV ) 1 2 antibody . Participation drug study w/I 60days 5 halflives previous drug . Participation 3 drug study 10months prior drug administration current protocol . Donation loss 100mL blood w/I 60days prior drug administration . Donation loss 1.5liters blood w/I 10months prior drug administration . Strenuous exercise w/I 96 hr . Prior admission clinical research center . Significant acute illness w/I 5days prior drug administration may impact safety assessment per judgement PI . Unsuitable vein infusion and/or venepuncture Surgery include surgery suturing via dental procedure would dehiscence w/I 28days dose . Any planned surgery dental procedure study least 30days follow . Presence nonhealing wound fracture . History bleed disorder History thromboembolic condition History gastrointestinal perforation fistulae . History orthostatic hypotension , faint spell , blackout reason . History hypertension Medically significant dental disease dental neglect sign symptom local systemic infection would likely require dental procedure course study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>MYL-1402O</keyword>
	<keyword>PK</keyword>
	<keyword>Avastin®</keyword>
	<keyword>biosimilarity</keyword>
	<keyword>male</keyword>
</DOC>